Arcutis Biotherapeutics Hits New 52-Week High of $21.30

Arcutis Biotherapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 21.30 on October 3, 2025. This achievement underscores the company's robust performance over the past year, with a remarkable increase of 164.19% compared to the S&P 500's 17.82% during the same period. The company has demonstrated consistent growth, reporting a 164.13% rise in net sales and positive results for the last seven consecutive quarters. Despite being a loss-making entity, Arcutis has shown resilience with its operating cash flow reaching its highest at USD -65.5 million. The return on capital employed (ROCE) also marked a notable high at -57.33%. Arcutis Biotherapeutics boasts a market capitalization of USD 2,080 million and maintains a strong institutional holding at 100%, indicating a solid backing from investors with substantial analytical resources. The stock's performance has outpaced the broader market, reflecting its competitive position within the industry.